radioisotope; micro-SPECT/CT; molecular imaging; micro-PET/CT
Viertl David, Buchegger Franz, Tourwé Dirk, Kosinski Marek, Stora Thierry, Bühler Léo, Prior John (2015), 152Tb and 68Ga-labeled DOTA-neurotensin analogs for targeting human ductal pancreatic cancers, in Nuklearmedizin/Nuclear Medicine
, StuttgartSchattauer, Stuttgart.
Molecular imaging allows better understanding of fundamental molecular pathways in a noninvasive manner. The use of preclinical imaging such as microPET (dual-photon) or mi-croSPECT (single-photon) is performed using radiopharmaceuticals specifically designed to image one cellular function or pathways in small animals (mice, rats) and can eventually be coupled with CT for anatomical imaging. As their clinical counterpart (PET/CT and SPECT/CT) already available at CHUV, they help localizing and quantifying biodistribution of diagnostic and therapeutic radiopharmaceuticals in vivo and can be repeatedly performed in vivo. Up to now, these microPET/SPECT techniques are not available at CHUV/UNIL and would be neces-sary to have to perform the first in vivo steps for many translational projects. This apparatus would be available to the whole CHUV/UNIL community performing preclinical research in oncology, cardiovascular and neurological diseases, provided that radiopharmaceu-ticals can be synthetized and send to CHUV (18F-based tracers with half-life of 110 min) or gen-erated in our nuclear medicine laboratory (68Ga-based tracers, 68-min half life). The proximity of the nuclear medicine (NUC) radiopharmaceutical (radiation-controlled zone at the B- and C-level) laboratory and the radiation therapy accelerators (RTH) allows benefiting from ideal conditions for preclinical small-animal research. Indeed, research involving large dose of radiation (therapeutical activities) necessitating SPECT imaging, image-intensive follow-up of animals (immunological processes performed every day or two) or short-lived radiotracers (Ga-68) cannot be performed in the PET-only scanner that is available to the scientific commu-nity at large at the EPFL-located CIBM PET laboratory.A palette of 5 projects that could uniquely benefit from the new microPET/SPECT/CT imaging equipment is given, covering from (1) fractionated targeted peptide receptor radiation ther-apy (PRRT) of tumors with radiolabeled bombesin and neurotensin analogs binding to gastrin releasing peptide (GRP) and neurotensin receptors; (2) cardiac regeneration; (3) Development of Molecular Imaging of Tumor Vasculature for the Early Detection of Hereditary Ovarian and Breast Cancer; (4) Development of Theranostics for Tumor Vasculature and (5) Spatial and temporal adaptive hypofractionated SBRT of orthotropic lung cancer in mice. A list of 6 potential projects that could additionally benefit from this equipment is given in the last section (4. Table of usage).